Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

ASCO and WHO to collaborate on quality indicators for cancer facilities

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL

Cancer Services Delivery: Focus on India

Diagnostic performance and survival outcome of SLNB procedure in breast cancer patients from a tertiary cancer care centre